Table 1

Clinical characteristics of randomized population

IDeg(A)IDeg(B)IGlar
Randomized, n596059
Exposed, n (%)59 (100)60 (100)59 (100)
Withdrawn, n (%)7 (12)5 (8)7 (12)
 Adverse event*2 (3)0 (0)1 (2)
 Noncompliance2 (3)1 (2)1 (2)
 Ineffective therapy1 (2)2 (3)0 (0)
 Other2 (3)2 (3)5 (9)
Completed trial, n (%)52 (88)55 (92)52 (88)
Sex, n (%)
 Men37 (63)37 (62)32 (54)
 Women22 (37)23 (38)27 (46)
Race, n (%)
 White58 (98)59 (98)57 (97)
 Black or African1 (2)0 (0)0 (0)
 Asian0 (0)1 (2)1 (2)
 Other0 (0)0 (0)1 (2)
Age (years)44.5 ± 12.745.6 ± 12.547.2 ± 13.5
Weight (kg)80.9 ± 11.880.5 ± 14.577.7 ± 14.2
BMI (kg/m2)27.2 ± 3.427.1 ± 3.626.3 ± 3.9
Diabetes duration (years)22.7 ± 14.620.8 ± 10.619.1 ± 10.8
Baseline A1C (%)8.4 ± 0.98.5 ± 1.08.3 ± 0.8
Baseline FPG (mmol/L)9.9 ± 3.310.3 ± 4.89.5 ± 3.8
Pretrial insulin regimen, n (%)
 Basal (once daily + mealtime)30 (51)30 (50)33 (56)
 Basal (twice daily + mealtime)25 (42)26 (43)25 (42)
 Premix insulin1 (2)1 (2)1 (2)
 Pump (CSII)2 (3)3 (5)0 (0)
 Mealtime only1 (2)0 (0)0 (0)
Basal insulin dose at baseline (units)29 ± 1228 ± 1323 ± 11
Mealtime insulin dose at baseline (units)31 ± 1530 ± 1429 ± 14
Total insulin dose at baseline (units)60 ± 2259 ± 2352 ± 21
  • *Adverse event withdrawals: diabetic ketoacidosis (IGlar), nausea (IDeg(A)), abdominal distension (IDeg(A)). CSII: continuous subcutaneous insulin infusion.